SIC
VRTX icon

Sigma Investment Counselors’s Vertex Pharmaceuticals VRTX Stock Holding History

Sigma Investment Counselors’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$4.29M Sell
9,617
-404
-4% -$188K 0.23% 69
2025
Q4 		$4.54M Sell
10,021
-118
-1% -$50.9K 0.23% 72
2025
Q3 		$3.97M Buy
10,139
+840
+9% +$351K 0.21% 75
2025
Q2 		$4.14M Buy
9,299
+548
+6% +$253K 0.23% 71
2025
Q1 		$4.24M Sell
8,751
-251
-3% -$117K 0.26% 62
2024
Q4 		$3.63M Buy
9,002
+65
+0.7% +$30.1K 0.21% 71
2024
Q3 		$4.16M Buy
8,937
+260
+3% +$125K 0.24% 67
2024
Q2 		$4.07M Buy
8,677
+515
+6% +$224K 0.25% 68
2024
Q1 		$3.41M Buy
8,162
+910
+13% +$385K 0.22% 72
2023
Q4 		$2.95M Buy
7,252
+5,909
+440% +$2.18M 0.21% 70
2023
Q3 		$467K Buy
1,343
+74
+6% +$25.9K 0.04% 130
2023
Q2 		$447K Hold
1,269
– – 0.03% 132
2023
Q1 		$400K Hold
1,269
– – 0.03% 139
2022
Q4 		$366K Sell
1,269
-13
-1% -$3.96K 0.03% 141
2022
Q3 		$371K Sell
1,282
-9
-0.7% -$2.59K 0.03% 134
2022
Q2 		$364K Hold
1,291
– – 0.03% 137
2022
Q1 		$337K Sell
1,291
-826
-39% -$196K 0.02% 147
2021
Q4 		$465K Buy
2,117
+127
+6% +$24.7K 0.03% 135
2021
Q3 		$361K Buy
1,990
+148
+8% +$28.9K 0.03% 141
2021
Q2 		$371K Buy
1,842
+27
+1% +$5.65K 0.03% 139
2021
Q1 		$390K Buy
1,815
+266
+17% +$58.4K 0.03% 134
2020
Q4 		$366K Buy
+1,549
New +$355K 0.03% 135
2020
Q3 		– Sell
-980
Closed -$285K – 155
2020
Q2 		$285K Buy
+980
New +$266K 0.03% 129
2019
Q3 		– Sell
-1,177
Closed -$216K – 162
2019
Q2 		$216K Buy
1,177
+22
+2% +$3.85K 0.03% 150
2019
Q1 		$212K Buy
+1,155
New +$213K 0.03% 148
2018
Q4 		– Sell
-1,169
Closed -$225K – 154
2018
Q3 		$225K Buy
+1,169
New +$208K 0.03% 139

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Sigma Investment Counselors's VRTX Position: Q1 2026 in Review

Sigma Investment Counselors reduced its Vertex Pharmaceuticals (VRTX) stake by 4% in Q1 2026, selling an estimated $188K and leaving 9,617 shares worth $4.29M. The position accounts for 0.23% of the portfolio, ranked #69.

Sigma Investment Counselors first reported a position in VRTX in Q3 2018 and has held it in 26 quarters since. The position peaked at $4.54M in Q4 2025. 1,687 funds tracked by Wall St. Rank hold VRTX as of Q1 2026.

  • Sigma Investment Counselors held 9,617 shares of Vertex Pharmaceuticals worth $4.29M as of Q1 2026.
  • Sigma Investment Counselors sold 404 Vertex Pharmaceuticals shares in Q1 2026, an estimated $188K.
  • Vertex Pharmaceuticals made up 0.23% of Sigma Investment Counselors's portfolio in Q1 2026, its #69 holding.
  • Sigma Investment Counselors first reported a position in Vertex Pharmaceuticals in Q3 2018 and has held it in 26 quarters since.
  • Sigma Investment Counselors's Vertex Pharmaceuticals position peaked at $4.54M in Q4 2025.
  • 1,687 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2026.

Based on Sigma Investment Counselors's 13F filing for Q1 2026, filed 29 Apr 2026.